Prodigiosin Serratia marcescens

A cell-permeable tripyrrole alkaloid compound that displays immunosuppressive and anti-tumor properties irrespective of p53 status and multidrug resistance. Shown to selectively upregulate p21^WAF/CIP1 and NAG-1 (nonsteroidal anti-inflammatory drug-activated gene 1) and downregulate survivin expression levels, induce mitochondria-mediated apoptosis and cell cycle arrest in tumor cells. Prevents FADD phosphorylation (IC₅₀ = 2.0 µM in A549-FKR cells) through inhibition of FADD-kinase CK1α (IC₅₀ ~ 6.0 µM in SW620-BGCR cells) and augments cisplatin (Cat. No. 232120)-induced apoptosis. Blocks NF-κB activation by decreasing pIκBα (by 63% at 3 µM) and IκBα levels in A549 cells, and shrinks tumor growth in A549-FKR tumor xenograft mouse model (3 mg/kg, i.p., o.d.).

Packaged under inert gas

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Schinske, K.A., et al. 2011. Mol. Cancer Ther.10, 1807.
Chang, C.C., et al. 2011. J. Biosci. Bioeng.5, 501
Ho, T.F., et al. 2009. Toxicol. Appl. Pharmacol.235, 253
Soto-Cerrato, V., et al. 2007.Mol. Cancer Ther.6, 362.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany